Cargando…
Gendered perspectives on women’s anabolic–androgenic steroid (AAS) usage practices
BACKGROUND: The masculinizing effects from anabolic–androgenic steroid (AAS) appear to be different between men and women, leading to calls for more gender-specific information regarding women and AAS use. This study sought to gather perspectives from both men and women on the unique challenges surr...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10127974/ https://www.ncbi.nlm.nih.gov/pubmed/37098574 http://dx.doi.org/10.1186/s12954-023-00786-x |
_version_ | 1785030514553389056 |
---|---|
author | Piatkowski, Tim Robertson, Jonathan Lamon, Severine Dunn, Matthew |
author_facet | Piatkowski, Tim Robertson, Jonathan Lamon, Severine Dunn, Matthew |
author_sort | Piatkowski, Tim |
collection | PubMed |
description | BACKGROUND: The masculinizing effects from anabolic–androgenic steroid (AAS) appear to be different between men and women, leading to calls for more gender-specific information regarding women and AAS use. This study sought to gather perspectives from both men and women on the unique challenges surrounding women’s use of AAS, irrespective of their personal use. Secondly, the study interrogated how women’s AAS practices differ from those of men specifically. METHODS: The data presented in this paper come from a subsample of participants who participated in a larger study investigating women and performance and image enhancing drug (PIED) use in Australia. Participants were included in the current analysis if they were: (i) males or females who competed with or coached female strength athletes using AAS and (ii) female and male strength athletes who used AAS. The final sample comprised 21 participants of which there was a proportion of males (n = 7) and females (n = 7) using AAS. RESULTS: Women’s choices in AAS selection were predominantly around oral compounds (e.g. Oxandrolone) as well as other PIEDs (e.g. Clenbuterol). Some women report the use of injectable AAS represents a change in the profile of the typical female user as it reportedly comes alongside drastic physical and psychological changes. CONCLUSIONS: The unique challenges facing women who use AAS are largely isolation and stigma, with little evidence-based practice or education being available to them online or through peer-groups. Future work may consider piloting harm reduction strategies that may be co-designed with this group. |
format | Online Article Text |
id | pubmed-10127974 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-101279742023-04-27 Gendered perspectives on women’s anabolic–androgenic steroid (AAS) usage practices Piatkowski, Tim Robertson, Jonathan Lamon, Severine Dunn, Matthew Harm Reduct J Research BACKGROUND: The masculinizing effects from anabolic–androgenic steroid (AAS) appear to be different between men and women, leading to calls for more gender-specific information regarding women and AAS use. This study sought to gather perspectives from both men and women on the unique challenges surrounding women’s use of AAS, irrespective of their personal use. Secondly, the study interrogated how women’s AAS practices differ from those of men specifically. METHODS: The data presented in this paper come from a subsample of participants who participated in a larger study investigating women and performance and image enhancing drug (PIED) use in Australia. Participants were included in the current analysis if they were: (i) males or females who competed with or coached female strength athletes using AAS and (ii) female and male strength athletes who used AAS. The final sample comprised 21 participants of which there was a proportion of males (n = 7) and females (n = 7) using AAS. RESULTS: Women’s choices in AAS selection were predominantly around oral compounds (e.g. Oxandrolone) as well as other PIEDs (e.g. Clenbuterol). Some women report the use of injectable AAS represents a change in the profile of the typical female user as it reportedly comes alongside drastic physical and psychological changes. CONCLUSIONS: The unique challenges facing women who use AAS are largely isolation and stigma, with little evidence-based practice or education being available to them online or through peer-groups. Future work may consider piloting harm reduction strategies that may be co-designed with this group. BioMed Central 2023-04-25 /pmc/articles/PMC10127974/ /pubmed/37098574 http://dx.doi.org/10.1186/s12954-023-00786-x Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Piatkowski, Tim Robertson, Jonathan Lamon, Severine Dunn, Matthew Gendered perspectives on women’s anabolic–androgenic steroid (AAS) usage practices |
title | Gendered perspectives on women’s anabolic–androgenic steroid (AAS) usage practices |
title_full | Gendered perspectives on women’s anabolic–androgenic steroid (AAS) usage practices |
title_fullStr | Gendered perspectives on women’s anabolic–androgenic steroid (AAS) usage practices |
title_full_unstemmed | Gendered perspectives on women’s anabolic–androgenic steroid (AAS) usage practices |
title_short | Gendered perspectives on women’s anabolic–androgenic steroid (AAS) usage practices |
title_sort | gendered perspectives on women’s anabolic–androgenic steroid (aas) usage practices |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10127974/ https://www.ncbi.nlm.nih.gov/pubmed/37098574 http://dx.doi.org/10.1186/s12954-023-00786-x |
work_keys_str_mv | AT piatkowskitim genderedperspectivesonwomensanabolicandrogenicsteroidaasusagepractices AT robertsonjonathan genderedperspectivesonwomensanabolicandrogenicsteroidaasusagepractices AT lamonseverine genderedperspectivesonwomensanabolicandrogenicsteroidaasusagepractices AT dunnmatthew genderedperspectivesonwomensanabolicandrogenicsteroidaasusagepractices |